HISTOLOGICAL REGRESSION OF BREAST-CANCER AFTER PRIMARY (NEOADJUVANT) CHEMOTHERAPY

被引:135
|
作者
SINN, HP [1 ]
SCHMID, H [1 ]
JUNKERMANN, H [1 ]
HUOBER, J [1 ]
LEPPIEN, G [1 ]
KAUFMANN, M [1 ]
BASTERT, G [1 ]
OTTO, HF [1 ]
机构
[1] UNIV HEIDELBERG, INST PATHOL, W-6900 HEIDELBERG, GERMANY
关键词
D O I
10.1055/s-2007-1022338
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Primary (neoadjuvant) chemotherapy of locally advanced breast carcinomas is performed to locally reduce the tumour mass and to improve the operability. Recently, the indication for primary chemotherapy has. been extended for preoperative treatment in breast conserving surgery. In an ongoing clinical trial we examined the resection specimens of 51 mammary carcinomas after primary chemotherapy. These patients had received a neoadjuvant therapy with epirubicine/cyclophosphamide for size reduction of large (> 3 cm) but operable tumours (pretreatment median tumour size 4.5 cm by mammography). The tumour response was evaluated pathologically and copared with the clinical tumour regression that was observed in over two-thirds of all cases. We classified the regressive changes using a semiquantitative scoring system from 0 to 4 (0 = no effect, 1 = resorption and tumour sclerosis, 2 = minimal residual invasive tumour [< 0.5 cm], 3 = residual noninvasive tumour only, 4 = no tumour detectable). The aim of this study was to evaluate the improvement of operability objectively and to correlate the histology of the primary tumour with the response to treatment. With invasive lobular carcinomas, the tumour size after therapy was reduced less than average and irrespective of the amount of histological tumour cell reduction, largely due to the stromal content of these neoplasms. Invasive ductal carcinomas with extensive or predominant intraductal component also underwent only a slight decrease in tumour size; this was because of the lack of tumour response with the intraductal component. Well differentiated tubular carcinomas were particularly resistant to primary chemotherapy. We conclude that the response of mammary carcinomas to primary chemotherapy can at least partially be explained by the tumour differentiation and is therefore to some extent predictable with careful evaluation of the pretreatment punch biopsy. The semiquantitative histological evaluation score suggested in this article permits the classification of the treatment effects and is therefore useful for further therapy planning.
引用
收藏
页码:552 / 558
页数:7
相关论文
共 50 条
  • [1] NEOADJUVANT CHEMOTHERAPY FOR PRIMARY BREAST-CANCER (BC)
    HORTOBAGYI, GN
    BUZDAR, AU
    MONTAGUE, E
    ROMSDAHL, M
    CANCER DRUG DELIVERY, 1986, 3 (01): : 54 - 54
  • [2] PRIMARY MEDICAL (NEOADJUVANT) CHEMOTHERAPY FOR OPERABLE BREAST-CANCER
    SMITH, IE
    JONES, AL
    OBRIEN, MER
    MCKINNA, JA
    SACKS, N
    BAUM, M
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (12) : 1796 - 1799
  • [3] PRIMARY MEDICAL (NEOADJUVANT) CHEMOTHERAPY FOR OPERABLE BREAST-CANCER
    SMITH, IE
    JONES, AL
    OBRIEN, MER
    MCKINNA, JA
    SACKS, N
    BAUM, M
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (04) : 592 - 595
  • [4] NEOADJUVANT CHEMOTHERAPY OF BREAST-CANCER
    JACQUILLAT, C
    BAILLET, F
    AUCLERC, G
    KHAYAT, D
    BLONDON, J
    AUCLERC, MF
    FACCHIN, T
    LEFRANC, JP
    WEIL, M
    DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, 1986, 12 (1-3) : 147 - 152
  • [5] NEOADJUVANT CHEMOTHERAPY IN OPERABLE BREAST-CANCER
    SCHOLL, SM
    ASSELAIN, B
    PALANGIE, T
    DORVAL, T
    JOUVE, M
    GIRALT, EG
    VILCOQ, J
    DURAND, JC
    POUILLART, P
    EUROPEAN JOURNAL OF CANCER, 1991, 27 (12) : 1668 - 1671
  • [6] NEOADJUVANT (PREOPERATIVE) CHEMOTHERAPY FOR BREAST-CANCER
    RAGAZ, J
    BAIRD, R
    REBBECK, P
    GOLDIE, J
    COLDMAN, A
    SPINELLI, J
    CANCER, 1985, 56 (04) : 719 - 724
  • [7] NEOADJUVANT CHEMOTHERAPY (CH) AND CONSERVATIVE RADIOTHERAPY (RT) OF PRIMARY BREAST-CANCER
    JACQUILLAT, C
    AUCLERC, G
    BAILLET, F
    BLONDON, J
    LEFRANC, JP
    MAYLIN, C
    MARAL, J
    WEIL, M
    BREAST CANCER RESEARCH AND TREATMENT, 1984, 4 (04) : 349 - 349
  • [8] PILOT TRIAL OF NEOADJUVANT CHEMOTHERAPY IN BREAST-CANCER
    POUILLART, P
    PALANGIE, T
    JOUVE, M
    GARCIAGIRALT, E
    DORVAL, T
    VILCOQ, JR
    DURAND, JC
    ROUSSEAU, JJ
    PILLERON, JP
    MATHIEU, G
    BATAINI, JP
    CANCER DRUG DELIVERY, 1986, 3 (01): : 56 - 56
  • [9] COS OF NEOADJUVANT CHEMOTHERAPY IN THE TREATMENT OF BREAST-CANCER
    ORGERIE, MB
    AVRIL, A
    DURAND, M
    BULLETIN DU CANCER, 1991, 78 (07) : 633 - 642
  • [10] NEOADJUVANT CHEMOTHERAPY IN BREAST-CANCER - PSYCHOLOGICAL INCIDENCES
    LEHMANN, A
    CANCER DRUG DELIVERY, 1986, 3 (01): : 79 - 79